The concept of prodromal Parkinson's disease

Journal of Parkinson's Disease

Volumn 5, Issue 4, 2015, Pages 681-697

  Mahlknecht, Philipp ^a,b   Seppi, Klaus ^a   Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

biomarker; early diagnosis; genetic and molecular biomarkers; neuroimaging; nonmotor symptoms (NMS); Parkinsons disease (PD); premotor PD

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER; TRACER;

CONSTIPATION; DOPPLER ECHOGRAPHY; ECHOGRAPHY; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HUMAN; HYPOSMIA; METABOLOMICS; MINIMALLY INVASIVE PROCEDURE; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASOMNIA; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PROTEOMICS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION; PATHOPHYSIOLOGY;

BIOMARKERS; HUMANS; PARKINSON DISEASE; PRODROMAL SYMPTOMS;

EID: 84952683160     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-150685     Document Type: Review

References (153)

1. Gibb WR, Lees AJ, 1988 The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 745 752
2. Greffard S, Verny M, Bonnet A-M, Beinis J-Y, Gallinari C, Meaume S, Piette F, Hauw J-J, Duyckaerts C, 2006 Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 63 584 588
3. Fearnley JM, Lees AJ, 1991 Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114 Pt 5 2283 2301
4. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U, 2002 Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249 Suppl. III/1-5
5. Del Tredici K, Braak H, 2012 Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord 27 597 607
6. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE, 2009 Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 15 S1 S5
7. Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, Mas N, Hofeneder D, Brücke T, Bayés A, Wenzel K, Infante J, Zach H, Pirker W, Posada IJ, Álvarez R, Ispierto L, De Fábregues O, Callén A, Palasí A, Aguilar M, Martí MJ, Valldeoriola F, Salamero M, Poewe W, Tolosa E, 2015 The onset of nonmotor symptoms in Parkinson's disease (The ONSET PDStudy). Mov Disord 30 229 237
8. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I, 2014 Prediagnostic presentations of Parkinson's disease in primary care: A case-control study. Lancet Neurol 14 57 64
9. Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D, 2011 The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. MovDisord 26 653 658
10. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti a, Blanchette PL, Popper JS, Ross GW, 2001 Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 456 462
11. Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, Bharucha AE, Rocca WA, 2009 Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology 73 1752 1758
12. Ishihara L, Brayne C, 2006 A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 113 211 220
13. Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA, 2000 Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study. Mov Disord 15 669 677
14. Postuma RB, Gagnon J-F, Bertrand J-A, Génier Marchand D, Montplaisir JY, 2015 Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials. Neurology 84 1104 1113
15. Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, Sanchez-Valle R, Vilaseca I, Lomeña F, Vilas D, LLadó A, Gaig C, Santamaria J, 2013 Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study. Lancet Neurol 12 443 453
16. Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W, 2013 The PRIPS study: Screening battery for subjects at risk for Parkinson's disease. Eur J Neurol 20 102 108
17. Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR, 2008 Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 63 167 173
18. Stern MB, Lang A, Poewe W, 2012 Toward a redefinition of Parkinson's disease. Mov Disord 27 54 60
19. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G, 2014 Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 29 454 462
20. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I, 2009 Neuropathological assessment of Parkinson's disease: Refining the diagnostic criteria. Lancet Neurol 8 1150 1157
21. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ, 1997 Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 41 58 64
22. Buchman AS, Shulman JM, Nag S, Leurgans SE, Arnold SE, Morris MC, Schneider JA, Bennett DA, 2012 Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 71 258 266
23. Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, White LR, 2004 Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 56 532 539
24. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JR, Ahlskog JE, 2008 Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. ActaNeuropathol 115 437 444
25. Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, Markesbery WR, Hardman J, Masaki K, Launer L, White LR, 2006 Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 21 2062 7
26. Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR, 2007 Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 22 1581 1586
27. Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W, 2014 Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 29 1767 1773
28. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J, 2001 [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57 2089 2094
29. Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi K, 2012 Neuroimaging: Current role in detecting pre-motor Parkinson's disease. Mov Disord 27 634 643
30. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ, 1998 Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64 314 319
31. De La Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, Mak E, McKenzie J, McCormick S, Sossi V, Ruth TJ, Lee CS, Calne DB, Stoessl AJ, 2011 Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 69 803 810
32. Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, Rudolf J, Herholz K, Heiss W-D, 2005 Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 62 378 382
33. Bezard E, Gross CE, Brotchie JM, 2003 Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26 215 221
34. Van Nuenen BFL, Van Eimeren T, Van Der Vegt JPM, Buhmann C, Klein C, Bloem BR, Siebner HR, 2009 Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach. Mov Disord 24 Suppl 2 S703 S710
35. Maetzler W, Hausdorff JM, 2012 Motor signs in the prodromal phase of Parkinson's disease. Mov Disord 27 627 633
36. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA, 1996 Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334 71 76
37. Louis ED, Bennett DA, 2007 Mild Parkinsonian signs: An overview of an emerging concept. Mov Disord 22 1681 1688
38. Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY, 2012 How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 135 1860 1870
39. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM, 2011 Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 69 193 197
40. Maetzler W, Mancini M, Liepelt-Scarfone I, Müller K, Becker C, van Lummel RC, Ainsworth E, Hobert M, Streffer J, Berg D, Chiari L, 2012 Impaired trunk stability in individuals at high risk for Parkinson's disease. PLoS One 7 e32240
41. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A, 2012 Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 72 893 901
42. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Knowles CH, Hardy J, Giovannoni G, Nageshwaran S, Osborne C, Lees AJ, Schrag A, 2014 PREDICT-PD: Identifying risk of Parkinson's disease in the community: Methods and baseline results. J Neurol NeurosurgPsychiatry 85 31 37
43. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Del Dotto P, 2009 The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24 1641 1649
44. Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Longo K, Cozzolino A, Giordano F, Rosa A De, Michele G De, Pellecchia MT, Barone P, 2013 Non-motor symptoms in early Parkinson's disease: A 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84 14 17
45. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, Barker RA, Burn DJ, 2013 The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 80 276 281
46. Poewe W, 2008 Non-motor symptoms in Parkinson's disease. Eur J Neurol 15 14 20
47. Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T, 2012 Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease. Mov Disord 27 617 626
48. Braak H, Del Tredici K, Rüb U, RaI De Vos, ENH Jansen Steur, Braak E, 2003 Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 197 211
49. Ponsen MM, Stoffers D, Wolters EC, Booij J, Berendse HW, 2010 Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry 81 396 399
50. Postuma RB, Gagnon J-F, Vendette M, Desjardins C, Montplaisir JY, 2011 Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 69 811 818
51. Ritz B, Lee P, Lassen CF, Arah OA, 2014 Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease. Neurology 83 1396 1402
52. Moccia M, Erro R, Picillo M, Vassallo E, Vitale C, Longo K, Amboni M, Santangelo G, Palladino R, Nardone A, Triassi M, Barone P, Pellecchia MT, 2015 Quitting smoking: An early non-motor feature of Parkinson's disease? Parkinsonism Relat Disord 21 216 220
53. Patel AJ, Sarwar AI, Jankovic J, Viswanathan A, 2014 Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. World Neurosurg 82 241.e1 241.e4
54. Schenck CH, Boeve BF, Mahowald MW, 2013 Delayed emergence of a parkinsonian disorder or dementia in 81 of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: A 16-year update on a previously reported series. Sleep Med 14 744 748
55. Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, Curb JD, Petrovitch H, 2005 Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65 1442 1446
56. Doty RL, 2012 Olfactory dysfunction in Parkinson disease. Nat Rev Neurol 8 329 339
57. Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, Johnston AN, Mellick GD, Herting B, Reichmann H, Hummel T, 2009 Prevalence of smell loss in Parkinson's disease-A multicenter study. Parkinsonism Relat Disord 15 490 494
58. Mahlknecht P, Iranzo A, Högl B, Frauscher B, Müller C, Santamaría J, Tolosa E, Serradell M, Mitterling T, Gschliesser V, Goebel G, Brugger F, Scherfler C, Poewe W, Seppi K, Sleep Innsbruck Barcelona Group 2015 Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 84 654 658
59. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW, 1986 Chronic behavioral disorders of human REM sleep: A new category of parasomnia. Sleep 9 293 308
60. Gagnon JF, Postuma RB, Mazza S, Doyon J, Montplaisir J, 2006 Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol 5 424 432
61. Mahlknecht P, Seppi K, Frauscher B, Kiechl S, Willeit J, Stockner H, Djamshidian A, Nocker M, Rastner V, Defrancesco M, Rungger G, Gasperi A, Poewe W, Högl B, 2015 Probable RBD and association with neurodegenerative disease markers: A population-based study. Mov Disord 30 1417 1421
62. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J, 2009 Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72 1296 1300
63. Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto T, Oertel W, Dauvilliers Y, Ju Y-E, Puligheddu M, Sonka K, Pelletier A, Santamaria J, Frauscher B, Leu-Semenescu S, Zucconi M, Terzaghi M, Miyamoto M, Unger MM, Carlander B, Fantini M-L, Montplaisir JY, 2015 Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study. Ann Neurol 77 830 839
64. Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR, 2007 Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 22 1581 1586
65. Pouclet H, Lebouvier T, Coron E, Bruley des Varannes S, Rouaud T, Roy M, Neunlist M, Derkinderen P, 2012 A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. Neurobiol Dis 45 305 309
66. Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH, 2012 Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 27 709 715
67. Siderowf A, Lang AE, 2012 Premotor Parkinson'sdisease: Concepts and definitions. Mov Disord 27 608 616
68. Definitions B, Group W, 2001 Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69 89 95
69. Ponsen MM, Stoffers D, Booij J, Van Eck-Smit BLF, Wolters EC, Berendse HW, 2004 Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 56 173 181
70. Iranzo A, Valldeoriola F, Lomeña F, Molinuevo JL, Serradell M, Salamero M, Cot A, Ros D, Pavía J, Santamaria J, Tolosa E, 2011 Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study. Lancet Neurol 10 797 805
71. Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K, PARS Investigators 2014 Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study. Neurology 83 1739 1746
72. Eberling JL, Dave KD, Frasier MA, 2013 α-synuclein imaging: A critical need for Parkinson's disease research. J Parkinsons Dis 3 565 567
73. Scherfler C, Frauscher B, Schocke M, Iranzo A, Gschliesser V, Seppi K, Santamaria J, Tolosa E, Högl B, Poewe W, 2011 White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 69 400 407
74. Unger MM, Belke M, Menzler K, Heverhagen JT, Keil B, Stiasny-Kolster K, Rosenow F, Diederich NJ, Mayer G, Möller JC, Oertel WH, Knake S, 2010 Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 33 767 773
75. Rolheiser TM, Fulton HG, Good KP, Fisk JD, McKelvey JR, Scherfler C, Khan NM, Leslie RA, Robertson HA, 2011 Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. J Neurol 258 1254 1260
76. Vaillancourt DE, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, Cornelia CL, Little DM, 2009 High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 72 1378 1384
77. Scherfler C, Schocke MF, Seppi K, Esterhammer R, Brenneis C, Jaschke W, Wenning GK, Poewe W, 2006 Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 129 538 542
78. Ibarretxe-Bilbao N, Junque C, Marti MJ, Valldeoriola F, Vendrell P, Bargallo N, Zarei M, Tolosa E, 2010 Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: A voxel-based diffusion tensor imaging study. Mov Disord 25 1888 1894
79. Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, Bowtell RW, Auer DP, Gowland PA, 2013 Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7 T MRI. Neurology 81 534 540
80. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP, 2014 The "swallow tail" appearance of the healthy nigrosome-a new accurate test of Parkinson'sdisease: A case-control and retrospective cross-sectional MRI study at 3T. PLoS One 9 e93814
81. Reiter E, Mueller C, Pinter B, Krismer F, Scherfler C, Esterhammer R, Kremser C, Schocke M, Wenning GK, Poewe W, Seppi K, 2015 Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord 30 1068 1076
82. Berg D, Gaenslen A, 2010 Place value of transcranial sonography in early diagnosis of Parkinson's disease. Neurodegener Dis 7 291 299
83. Mahlknecht P, Seppi K, Stockner H, Nocker M, Scherfler C, Kiechl S, Willeit J, Schmidauer C, Gasperi A, Rungger G, Poewe W, 2013 Substantia nigra hyperechogenicity as a marker for parkinson's disease: A population-based study. Neurodegener Dis 12 212 218
84. Behnke S, Runkel A, Kassar HAS, Ortmann M, Guidez D, Dillmann U, Fassbender K, Spiegel J, 2013 Long-term course of substantia nigra hyperechogenicity in Parkinson's disease. Mov Disord 28 455 459
85. Mahlknecht P, Stockner H, Nocker M, Kiechl S, Willeit J, Scherfler C, Sojer M, Gasperi A, Rungger G, Poewe W, Seppi K, 2012 A follow-up study of substantia nigra echogenicity in healthy adults. Mov Disord 27 1196 1197
86. Iranzo A, Stockner H, Serradell M, Seppi K, Valldeoriola F, Frauscher B, Molinuevo JL, Vilaseca I, Mitterling T, Gaig C, Vilas D, Santamaria J, Högl B, Tolosa E, Poewe W, 2014 Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. Mov Disord 29 1774 1780
87. Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G, 2002 Echogenicity of the substantia nigra: Association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59 999 1005
88. Berg D, Godau J, Riederer P, Gerlach M, Arzberger T, 2010 Microglia activation is related to substantia nigra echogenicity. J Neural Transm 117 1287 1292
89. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW, 1999 Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53 1026 1031
90. Behnke S, Schroeder U, Dillmann U, Buchholz HG, Schreckenberger M, Fuss G, Reith W, Berg D, Krick CM, 2009 Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 47 1237 1243
91. Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W, 2011 Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: A 37-month 3-center study of 1847 older persons. Arch Neurol 68 932 937
92. Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, Liepelt-Scarfone I, Pausch C, Schneider N, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Gasser T, Poewe W, 2013 Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 28 216 219
93. Mahlknecht P, Kiechl S, Stockner H, Willeit J, Gasperi A, Poewe W, Seppi K, 2015 Predictors for mild parkinsonian signs: A prospective population-based study. Parkinsonism Relat Disord 21 321 324
94. Sierra M, Sánchez-Juan P, Martínez-Rodríguez MI, González-Aramburu I, García-Gorostiaga I, Quirce MR, Palacio E, Carril JM, Berciano J, Combarros O, Infante J, 2013 Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 80 621 626
95. Trinh J, Farrer M, 2013 Advances in the genetics of Parkinson disease. Nat Rev Neurol 9 445 454
96. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen C-M, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung H-C, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith a, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen G-J, Lesage S, Marder K, Mata IF, Mirelman a, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone a, Rogaeva E, Rolfs a, Rosenbaum H, Rozenberg R, Samii a, Samaddar T, Schulte C, Sharma M, Singleton a, Spitz M, Tan E-K, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu Y-R, Zabetian CP, Zhao Y, Ziegler SG, 2009 Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361 1651 1661
97. Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, Pollak P, Bonaïti B, Bonaïti-Pellié C, Brice A, 2012 Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 78 417 420
98. Brockmann K, Srulijes K, Pflederer S, Hauser A-K, Schulte C, Maetzler W, Gasser T, Berg D, 2015 GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 30 407 411
99. Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AHV, 2015 Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol 72 201 208
100. Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, Bras J, Hersheson J, Stamelou M, Pittman AM, Noyce AJ, Mok KY, Opladen T, Kunstmann E, Hodecker S, Münchau A, Volkmann J, Samnick S, Sidle K, Nanji T, Sweeney MG, Houlden H, Batla A, Zecchinelli AL, Pezzoli G, Marotta G, Lees A, Alegria P, Krack P, Cormier-Dequaire F, Lesage S, Brice A, Heutink P, Gasser T, Lubbe SJ, Morris HR, Taba P, Koks S, Majounie E, Raphael Gibbs J, Singleton A, Hardy J, Klebe S, Bhatia KP, Wood NW, 2014 Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137 2480 2492
101. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW, 2011 Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377 641 649
102. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23 and Me; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB, 2014 Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46 989 993
103. Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP, 23andMe Genetic Epidemiology of Parkinson's Disease Consortium; International Parkinson's Disease Genomics Consortium; Parkinson's Disease GWAS Consortium; Wellcome Trust Case Control Consortium 2) Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JP, Bertram L, 2012 Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDgene database. PLoS Genet 8 4 13
104. Escott-Price V, Nalls MA, Morris HR, Lubbe S, Brice A, Gasser T, Heutink P, Wood NW, Hardy J, Singleton AB, Williams NM, 2015 Polygenic risk of Parkinson disease is correlated with disease age at onset. Ann Neurol 77 582 591
105. Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M5, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB, Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators 2015 Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: A population-based modelling study. Lancet Neurol 14 1002 1009
106. Pankratz N, Beecham GW, Destefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T, 2012 Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2. Ann Neurol 71 370 384
107. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P, 2013 Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 9 131 140
108. Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Sáez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C, 2012 Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: An update. Biomark Med 6 419 430
109. Parkinson ProgressionMarker, Initiative 2011 The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95 629 635
110. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM, Parkinson's Progression Markers Initiative 2013 Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70 1277 1287
111. Gao L, Tang H, Nie K, Wang L, Zhao J, Gan R, Huang J, Zhu R, Feng S, Duan Z, Zhang Y, Wang L, 2015 Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: A systematic review and meta-analysis. Int J Neurosci 125 645 654
112. Zetterberg H, Petzold M, Magdalinou N, 2014 Cerebrospinal fluid α-synuclein levels in Parkinson's disease-changed or unchanged? Eur. J Neurol 21 365 367
113. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J, 2010 Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 480 78 82
114. Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VMY, Trojanowski JQ, Yearout D, Leverenz JB, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS, 2013 Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 74 119 127
115. Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS, 2015 Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients. Mov Disord 10.1002/mds.26290
116. Lee Y, Lin C, Wu R-M, Lin M-S, Lin J-W, Chang C-H, Lai M-S, 2013 Discontinuation of statin therapy associates with Parkinson disease: A population-based study. Neurology 81 410 416
117. Huang X, Alonso A, Guo X, Umbach DM, Lichtenstein ML, Ballantyne CM, Mailman RB, Mosley TH, Chen H, 2015 Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study. Mov Disord 30 552 559
118. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J, 2008 Total cholesterol and the risk of Parkinson disease. Neurology 70 1972 1979
119. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW, 2008 Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu-Asia Aging Study. Mov Disord 23 1013 1018
120. Serafin A, Foco L, Zanigni S, Blankenburg H, Picard A, Zanon A, Giannini G, Pichler I, Facheris MF, Cortelli P, Pramstaller PP, Hicks AA, Domingues FS, Schwienbacher C, 2015 Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD. Neurology 84 645 653
121. Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, Forsgren L, Neuman LA, Tan AC, 2012 Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. J Parkinsons Dis 2 321 331
122. McKhann GM, 2011 Changing concepts of Alzheimerdisease. JAMA 305 2458 2459
123. Mollenhauer B, Zhang J, 2012 Biochemical premotor biomarkers for Parkinson's disease. Mov Disord 27 644 650
124. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J, 2010 DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133 713 726
125. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J, 2011 Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69 570 580
126. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG, 2011 α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. Lancet Neurol 10 230 240
127. Van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WDJ, 2014 Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 21 388 394
128. Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel-Döring F, Ebentheuer J, Trenkwalder C, Schlossmacher MG, 2013 Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 532 44 48
129. Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM-Y, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J, 2012 Phosphorylated alpha-synuclein in Parkinson's disease. Sci Transl Med 4. 121ra20-121ra20
130. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka a, Nakagawa M, El-Agnaf OM, 2010 Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75 1766 1772
131. Wang N, Gibbons CH, Lafo J, Freeman BSR, 2013 α-Synuclein in cutaneous autonomic nerves. Neurology 81 1604 1610
132. Doppler K, Ebert S, Üçeyler N, Trenkwalder C, Ebentheuer J, Volkmann J, Sommer C, 2014 Cutaneous neuropathy in Parkinson's disease: A window into brain pathology. Acta Neuropathol 128 99 109
133. Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, Capellari S, Avoni P, Baruzzi A, Liguori R, 2014 Skin nerve a-synuclein deposits A biomarker for idiopathic Parkinson disease. Neurology 82 1362 1369
134. Adler CH, Dugger BN, Hinni ML, Lott DG, Driver-Dunckley E, Hidalgo J, Henry-Watson J, Serrano G, Sue LI, Nagel T, Duffy A, Shill HA, Akiyama H, Walker DG, Beach TG, 2014 Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 82 858 864
135. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, Zhang J, 2011 Salivary alpha-synuclein and DJ-1: Potential biomarkers for Parkinson's disease. Brain 134 Pt 7 e178
136. Schneider SA, Boettner M, Alexoudi A, Zorenkov D, Deuschl G, Wedel T, 2015 Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature. Eur J Neurol 10.1111/ene.12753
137. Lebouvier T, Neunlist M, des Varannes SB, Coron E, Drouard A, N'Guyen JM, Chaumette T, Tasselli M, Paillusson S, Flamand M, Galmiche JP, Damier P, Derkinderen P, 2010 Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 5 1 9
138. Pouclet H, Lebouvier T, Coron E, Des Varannes SB, Neunlist M, Derkinderen P, 2012 A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease. Neurogastroenterol Motil 24 202 205
139. Visanji NP, Marras C, Kern DS, Al Dakheel A, Gao A, Liu LWC, Lang AE, Hazrati L-N, 2015 Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 84 609 616
140. Sprenger F, Gelpi E, Navarro-Otano J, Offner F, Vilas D, Valladeoriola F, Pont-Sunyer C, Aldecoa I, Gaig C, Gines A, Cuatrecases M, Hogl B, Frauscher B, Iranzo A, Wenning GK, Vogel W, Tolosa E, Poewe W, 2015 Enteric nervous system alpha-synuclein immunoreactivity in idopathic REM sleep behavior disorder. Neurology. Oct 16. pii:10.1212/WNL.0000000000002126. [Epub ahead of print]
141. Sánchez-Ferro Á Rábano A, Catalán MJ, Rodríguez-Valcárcel FC, Fernández Díez S, Herreros-Rodríguez J, García-Cobos E, Álvarez-Santullano MM, López-Manzanares L, Mosqueira AJ, Vela Desojo L, López-Lozano JJ, López-Valdás E, Sánchez-Sánchez R, Molina-Arjona JA, 2015 gastric detection of α-synuclein inclusions in Parkinson's disease. Mov Disord 30 517 524
142. Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, Carroll C, 2014 Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol 127 235 241
143. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH, 2012 Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases. Mov Disord 27 716 719
144. Böttner M, Zorenkov D, Hellwig I, Barrenschee M, Harde J, Fricke T, Deuschl G, Egberts J-H, Becker T, Fritscher-Ravens A, Arlt A, Wedel T, 2012 Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis 48 474 480
145. Folgoas E, Lebouvier T, Leclair-Visonneau L, Cersosimo M-G, Barthelaix A, Derkinderen P, Letournel F, 2013 Diagnostic value of minor salivary glands biopsy for the detection of Lewy pathology. Neurosci Lett 551 62 64
146. Beach TG, White CL, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH, 2009 Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 117 169 174
147. Witt M, Bormann K, Gudziol V, Pehlke K, Barth K, Minovi A, Hähner A, Reichmann H, Hummel T, 2009 Biopsies of olfactory epithelium in patients with Parkinson's disease. Mov Disord 24 906 914
148. Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P, 2015 Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 30 350 358
149. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM, 2015 Colonic bacterial composition in Parkinson's disease. Mov Disord 30 1351 1360
150. Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P, 2015 Linking smoking, coffee, urate, and Parkinson's disease-a role for gut microbiota? J Parkinsons Dis 5 255 262
151. Angot E, Steiner JA, Hansen C, Li JY, Brundin P, 2010 Are synucleinopathies prion-like disorders? Lancet Neurol 9 1128 1138
152. Woerman AL, Stöhr J, Aoyagi A, Rampersaud R, Krejciova Z, Watts JC, Ohyama T, Patel S, Widjaja K, Oehler A, Sanders DW, Diamond MI, Seeley WW, Middleton LT, Gentleman SM, Mordes DA, Südhof TC, Giles K, Prusiner SB, 2015 Propagation of prions causing synucleinopathies in cultured cells. Proc Natl Acad Sci U S A 112 E4949 E4958
153. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G, 2015 MDS research criteria for prodromal Parkinson's disease. Mov Disord 30 1600 1611